• Je něco špatně v tomto záznamu ?

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1

E. Tausch, P. Beck, RF. Schlenk, BJ. Jebaraj, A. Dolnik, DY. Yosifov, P. Hillmen, F. Offner, A. Janssens, GK. Babu, S. Grosicki, J. Mayer, P. Panagiotidis, A. McKeown, IV. Gupta, A. Skorupa, C. Pallaud, L. Bullinger, D. Mertens, H. Döhner, S. Stilgenbauer

. 2020 ; 105 (10) : 2440-2447. [pub] 20201001

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020053

Next generation sequencing studies in Chronic lymphocytic leukemia (CLL) have revealed novel genetic variants that have been associated with disease characteristics and outcome. The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL)). Baseline samples were available from 383 patients (85.6%) representative of the total trial cohort. Mutations were analyzed by amplicon-based targeted next generation sequencing (tNGS). In 52.2% of patients we found at least one mutation and the incidence was highest in NOTCH1 (17.0%), followed by SF3B1 (14.1%), ATM (11.7%), TP53 (10.2%), POT1 (7.0%), RPS15 (4.4%), FBXW7 (3.4%), MYD88 (2.6%) and BIRC3 (2.3%). While most mutations lacked prognostic significance, TP53 (HR2.02,p<0.01), SF3B1 (HR1.66,p=0.01) and NOTCH1 (HR1.39,p=0.03) were associated with inferior PFS in univariate analysis. Multivariate analysis confirmed the independent prognostic role of TP53 for PFS (HR1.71,p=0.04) and OS (HR2.78,p=0.02) and of SF3B1 for PFS only (HR1.52,p=0.02). Notably, NOTCH1 mutation status separates patients with a strong and a weak benefit from ofatumumab addition to CHL (NOTCH1wt:HR0.50,p<0.01, NOTCH1mut:HR0.81,p=0.45). In summary, TP53 and SF3B1 were confirmed as independent prognostic and NOTCH1 as a predictive factor for reduced ofatumumab efficacy in a randomized chemo (immune)therapy CLL trial. These results validate NGS-based mutation analysis in a multicenter trial and provide a basis for expanding molecular testing in the prognostic workup of patients with CLL. ClinicalTrials.gov registration number: NCT00748189.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020053
003      
CZ-PrNML
005      
20210830101647.0
007      
ta
008      
210728s2020 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2019.229161 $2 doi
035    __
$a (PubMed)33054084
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Tausch, Eugen $u Department of Internal Medicine III, Ulm University, Ulm, Germany
245    10
$a Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 / $c E. Tausch, P. Beck, RF. Schlenk, BJ. Jebaraj, A. Dolnik, DY. Yosifov, P. Hillmen, F. Offner, A. Janssens, GK. Babu, S. Grosicki, J. Mayer, P. Panagiotidis, A. McKeown, IV. Gupta, A. Skorupa, C. Pallaud, L. Bullinger, D. Mertens, H. Döhner, S. Stilgenbauer
520    9_
$a Next generation sequencing studies in Chronic lymphocytic leukemia (CLL) have revealed novel genetic variants that have been associated with disease characteristics and outcome. The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL)). Baseline samples were available from 383 patients (85.6%) representative of the total trial cohort. Mutations were analyzed by amplicon-based targeted next generation sequencing (tNGS). In 52.2% of patients we found at least one mutation and the incidence was highest in NOTCH1 (17.0%), followed by SF3B1 (14.1%), ATM (11.7%), TP53 (10.2%), POT1 (7.0%), RPS15 (4.4%), FBXW7 (3.4%), MYD88 (2.6%) and BIRC3 (2.3%). While most mutations lacked prognostic significance, TP53 (HR2.02,p<0.01), SF3B1 (HR1.66,p=0.01) and NOTCH1 (HR1.39,p=0.03) were associated with inferior PFS in univariate analysis. Multivariate analysis confirmed the independent prognostic role of TP53 for PFS (HR1.71,p=0.04) and OS (HR2.78,p=0.02) and of SF3B1 for PFS only (HR1.52,p=0.02). Notably, NOTCH1 mutation status separates patients with a strong and a weak benefit from ofatumumab addition to CHL (NOTCH1wt:HR0.50,p<0.01, NOTCH1mut:HR0.81,p=0.45). In summary, TP53 and SF3B1 were confirmed as independent prognostic and NOTCH1 as a predictive factor for reduced ofatumumab efficacy in a randomized chemo (immune)therapy CLL trial. These results validate NGS-based mutation analysis in a multicenter trial and provide a basis for expanding molecular testing in the prognostic workup of patients with CLL. ClinicalTrials.gov registration number: NCT00748189.
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x genetika $7 D015451
650    _2
$a mutace $7 D009154
650    _2
$a fosfoproteiny $x genetika $7 D010750
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a sestřihové faktory $x genetika $7 D000072260
650    _2
$a receptor Notch1 $x genetika $7 D051881
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Beck, Philipp $u Department of Internal Medicine III, Ulm University, Ulm, Germany
700    1_
$a Schlenk, Richard F $u Department of Internal Medicine III, Ulm University, Ulm, Germany
700    1_
$a Jebaraj, Billy J $u Department of Internal Medicine III, Ulm University, Ulm, Germany
700    1_
$a Dolnik, Anna $u Klinik fur Innere Medizin fur Hematologie, Onkologie und Tumorimmunologie, Charité Berlin
700    1_
$a Yosifov, Deyan Y $u Department of Internal Medicine III, Ulm University, Ulm, Germany
700    1_
$a Hillmen, Peter $u Department of Haematology, St. James's University Hospital, Leeds, United Kingdom
700    1_
$a Offner, Fritz $u Universitair Ziekenhuis Gent, Gent, Belgium
700    1_
$a Janssens, Ann $u Universitair Ziekenhuis Leuven, Leuven, Belgium
700    1_
$a Babu, Govind K $u Kidwai Memorial Institute of Oncology, Bangalore, India
700    1_
$a Grosicki, Sebastian $u Hematology and Cancer Prevention,School of Public Health,Silesian Medical University,Katowice,Poland
700    1_
$a Mayer, Jiri $u Department of Haematology-Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Panagiotidis, Panagiotis $u University of Athens, Laikon General Hospital, Athens, Greece
700    1_
$a McKeown, Astrid $u Oncology Global Medicines Development, AstraZeneca, Melbourn, UK
700    1_
$a Gupta, Ira V $u GSK Oncology, GlaxoSmithKline, London, UK
700    1_
$a Skorupa, Alexandra $u Novartis Pharma GmbH, Nürnberg, Germany
700    1_
$a Pallaud, Celine $u Novartis AG, Basel, Switzerland
700    1_
$a Bullinger, Lars $u Klinik fur Innere Medizin fur Hematologie, Onkologie und Tumorimmunologie, Charité, Berlin
700    1_
$a Mertens, Daniel $u Department of Internal Medicine III, Ulm University, Ulm, Germany
700    1_
$a Döhner, Hartmut $u Department of Internal Medicine III, Ulm University, Ulm, Germany
700    1_
$a Stilgenbauer, Stephan $u Department of Internal Medicine III, Ulm University, Ulm, Germany
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 105, č. 10 (2020), s. 2440-2447
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33054084 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101647 $b ABA008
999    __
$a ok $b bmc $g 1690775 $s 1140499
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 105 $c 10 $d 2440-2447 $e 20201001 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace